Company profile: WuXi XDC
1.1 - Company Overview
Company description
- Provider of end-to-end CRDMO services for bioconjugates, including antibody-drug conjugates, spanning discovery, process development (scale-up, tech-transfer), analytical development, formulation/DP design, and GMP manufacturing of mAb intermediates and conjugations (antibodies and payload-linkers) from preclinical to commercial supply.
Products and services
- End-to-End CRDMO Services: Integrated service delivering contract research, development, and manufacturing for antibody-drug conjugates and other bioconjugates, covering all stages from discovery to commercial production
- GMP mAb Intermediate and Conjugation Manufacturing: GMP-compliant manufacturing of drug substances and intermediates—including antibodies and payload-linkers—for clinical and commercial supply, covering monoclonal antibody production and conjugation steps for bioconjugates
- Bioconjugation Process Development: CMC-focused process development, scale-up, and tech-transfer for ADCs and other bioconjugates, supporting Chemistry, Manufacturing, and Controls development activities from early process definition through transfer to manufacturing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to WuXi XDC
Genflow Biosciences
HQ: United States
Website
- Description: Provider of synthetic biology-based gene therapies to delay or stop aging in humans and dogs, focused on the development and promotion of creative treatments that target aging to extend life expectancy in both humans and canines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genflow Biosciences company profile →
DFE Pharma
HQ: Germany
Website
- Description: Provider of excipient solutions for pharmaceutical, biopharmaceutical, and nutraceutical industries, developing, producing, and supplying functional excipients used as fillers, binders, disintegrants, and stabilizers. Offers BioHale excipients to stabilize biologics across parenteral, inhalation, oral, and ophthalmic routes, an online formulation tool, and technical, regulatory, quality, and formulation support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DFE Pharma company profile →
Zwiers Regulatory
HQ: The Netherlands
Website
- Description: Provider of consulting services focused on integrated development for pharmaceuticals and devices, pharmacovigilance, and regulatory affairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zwiers Regulatory company profile →
Beryllium
HQ: United States
Website
- Description: Provider of specialized drug discovery contract research services, collaborating with leading pharmaceutical, innovative biotechnology, and academic partners based on its innovative drug discovery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beryllium company profile →
Exela Pharma Sciences
HQ: United States
Website
- Description: Provider of sterile injectable pharmaceuticals for the healthcare sector, offering Sodium Bicarbonate Injection (electrolyte replenisher/systemic alkalizer), Caffeine Citrate Injection, ELCYS (cysteine hydrochloride injection), GLYRX-PF (synthetic anticholinergic), Nipride RTU (sodium nitroprusside), and Caffeine Citrate Oral Solution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exela Pharma Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for WuXi XDC
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to WuXi XDC
2.2 - Growth funds investing in similar companies to WuXi XDC
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for WuXi XDC
4.2 - Public trading comparable groups for WuXi XDC
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →